|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/485 | |
| A61K 31/555 | |||
| A61K 31/675 | |||
| A61K 31/7068 | |||
| A61K 45/06 | |||
| A61P 35/00 | |||
| G01N 33/50 |
| (11) | Patento numeris | 3600433 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 18717108.7 |
| Europos patento paraiškos padavimo data | 2018-03-28 | |
| (97) | Europos patento paraiškos paskelbimo data | 2020-02-05 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-05-05 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/GB2018/050843 |
| Data | 2018-03-28 |
| (87) | Numeris | WO 2018/178690 |
| Data | 2018-10-04 |
| (30) | Numeris | Data | Šalis |
| 201704910 | 2017-03-28 | GB | |
| 201718806 | 2017-11-14 | GB |
| (72) |
DALGLEISH, Angus, GB
LUI, Wai, GB
|
| (73) |
LDN Pharma Limited,
25 Moorgate, London, EC2R 6AY,
GB
|
| (54) | AN AGENT THAT INCREASES THE EXPRESSSION OF THE BCL2-ASSOCIATED AGONIST OF CELL DEATH FOR THE TREATMENT OF CANCER |
| AN AGENT THAT INCREASES THE EXPRESSSION OF THE BCL2-ASSOCIATED AGONIST OF CELL DEATH FOR THE TREATMENT OF CANCER |